Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

ManageEngine Recognized as an April 2019 Gartner Peer Insights Customers’ Choice for Unified Endpoint Management Tools

Published

on

Reading Time: 4 minutes

Desktop Central, Mobile Device Manager Plus Earn Distinction Based on
65+ Reviews from UEM Professionals Worldwide

PLEASANTON, Calif.–(BUSINESS WIRE)–ManageEngine,
the IT management division of Zoho Corporation, today announced that it
has been named a 2019 Gartner
Peer Insights Customers’ Choice
for its unified endpoint management
(UEM) software, Desktop Central and Mobile Device Manager Plus.
ManageEngine earned this distinction through 71 end-user reviews with an
overall rating of 4.5 out of 5 in the unified endpoint management market
as of May 17, 2019. Notably, 87 percent of the reviewers noted a
“willingness to recommend” the software to enterprise-level customers as
of May 28, 2019.

Read reviews of ManageEngine UEM on Gartner Peer Insights at https://gtnr.it/2HhPxLW. Read
reviews of Desktop Central on Gartner Peer Insights at https://gtnr.it/2PV5xYc.

Click
to tweet
this news.

“We pioneered mobile device management in 2013, when mobile devices
started proliferating in the workplace. Back then, we had the foresight
to integrate mobile device management with our UEM solution, Desktop
Central. Today, mobility dominates UEM concerns,” said Mathivanan
Venkatachalam, ManageEngine vice president. “We believe this Customers’
Choice distinction reflects how much our customers value the foresight
and innovation that have made Desktop Central and Mobile Device Manager
Plus the most widely-implemented UEM solutions around the world. We’re
honored by our end users’ recognition, and we’re continuing to push the
UEM envelope on their behalf.”

ManageEngine was also recognized by Gartner analysts in the July 2018
Magic Quadrant for Unified Endpoint Management Tools.

Customer Kudos for Desktop Central

It’s
Our Swiss Army Knife!
IT Director from the transportation industry:
“My team has been using Desktop Central for over four years, and it has
been a lifesaver for my team. We can now quickly and remotely deploy
software, updates, patches, fixes, registry edits and configurations. It
has significantly improved productivity with fewer touches in the field
leading to more satisfied users and quicker response times.”

After
a Major Search and Year Of Use, This One Is Far and Away the Best Bang
for The Buck
. IT Manager with a government organization: “We are a
regional library system with seven remote branches, 110 staff and 378
CPUs that we manage with Desktop Central. I agree with my best tech, ‘If
you want to take away Desktop Central, you’ll have to pry it out of my
cold, dead hands.’”

Complete
Endpoint Management Tool, Easy Installation, and Deployment
. CIO
from the services industry: “It is one of the best end point management
tools. You can manage your assets, OS, and software deployment. You can
also pull or schedule your AD Reports.”

Easy
Implementation, Best Support Ever, and Best Customer Feedback/Request
Model
. Senior Information Technology Specialist with a government
organization: “Desktop Central is very easy to set up and
administer. Within a couple of hours you can be set up and going,
managing all your systems… It has reduced the amount of time it takes to
manage our systems greatly!”

Simple
Installation and Productive In Minutes
. Senior Manager
Infrastructure and Compliance from the services industry: “I have worked
with the ManageEngine Desktop Central tool now for a number of years and
brought it into three different companies…There is nothing that
compares to the cost effective nature of this product.”

Pricing and Availability

For information on availability and pricing for Desktop Central, visit www.manageengine.com/products/desktop-central/edition-comparison-matrix.html.

About Gartner Peer Insights

Peer Insights is an online platform of ratings and reviews of IT
software and services that are written and read by IT professionals and
technology decision makers. The goal is to help IT leaders make more
insightful purchase decisions and help technology providers improve
their products by receiving objective, unbiased feedback from their
customers. Gartner Peer Insights includes more than 215,000 verified
reviews in over 340 markets. For more information, please visit www.gartner.com/reviews/home.

Gartner Peer Insights Customers’ Choice constitute the subjective
opinions of individual end-user reviews, ratings, and data applied
against a documented methodology; they neither represent the views of,
nor constitute an endorsement by, Gartner or its affiliates.

Gartner does not endorse any vendor, product or service depicted in its
research publications, and does not advise technology users to select
only those vendors with the highest ratings or other designation.
Gartner research publications consist of the opinions of Gartner’s
research organization and should not be construed as statements of fact.
Gartner disclaims all warranties, express or implied, with respect to
this research, including any warranties of merchantability or fitness
for a particular purpose.

About Desktop Central

ManageEngine Desktop Central is a unified endpoint management solution
that helps in managing thousands of servers, desktops, and mobile
devices from a central location. It automates the complete desktop and
mobile device management life cycle, ranging from a simple system
configuration to complex software deployment. Used by more than 8,000
customers around the globe, Desktop Central helps businesses cut costs
on IT infrastructure, achieve operational efficiency, improve
productivity, and combat network vulnerabilities. For more information,
visit www.manageengine.com/desktop-central.

About ManageEngine

ManageEngine is the enterprise IT management division of Zoho
Corporation. Established and emerging enterprises – including more than
60 percent of the Fortune 500 – rely on our real-time IT management
tools to ensure optimal performance of their IT infrastructure,
including networks, servers, applications, desktops and more. We have
offices worldwide, including the United States, the Netherlands, India,
Singapore, Japan, China, and Australia as well as a network of 200+
global partners to help organizations tightly align their businesses and
IT. For more information, please visit www.manageengine.com;
follow the company blog at blogs.manageengine.com and
on LinkedIn at www.linkedin.com/company/manageengine,
Facebook at www.facebook.com/ManageEngine
and Twitter @ManageEngine.

Contacts

Ahana Vissa
ManageEngine
(925) 924-9500, ext. 7292
[email protected]

Sean Welch
PAN Communications
(407) 734-7330
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland

Published

on

Continue Reading

Cannabis

Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa

Published

on

Continue Reading

Innocan

Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey

Published

on

innocan-pharma-reports-breakthrough-in-a-pre-clinical-trial:-liposomal-cbd-injection-restores-mobility-to-an-amputee-female-donkey

HERZLIYA, Israel and ALGARY, AB, May 9, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the successful pre-clinical treatment with a liposomal-CBD injection in a female donkey. Innocan’s innovative therapy provided immediate noticeable pain relief and improved mobility.

Miri, a 7-year-old female donkey, underwent amputation of her right front limb at a young age, resulting in a weight burden primarily borne by her left front limb. Consequently, she developed laminitis in her left front limb, an inflammatory disease affecting the soft tissue that connects the foot bone to the hoof, seemingly causing extreme pain and limited mobility. Over time, Miri’s condition worsened, culminating in the formation of a abscess in the affected hoof, which appeared to have intensified her pain. Despite receiving pain relief medications, Miri found no respite, was unable to move, and her caregivers were advised to euthanize her.

As an act of compassionate therapy, the female donkey was administered a liposomal-CBD injection. The effect was immediate, with Miri becoming active and roaming the farm. Following the liposomal-CBD injection, the abscess in her affected foot healed, and Miri regained her ability to walk and move as she did before her laminitis developed.

“Thanks to our innovative liposomal-CBD injection, we are thrilled to have brought relief to Miri, eliminating the need for euthanasia,” commented Iris Bincovich, CEO of Innocan. “Once again, Innocan has shown liposomal-CBD to be effectively active for pain relief and well-being. We see this pre-clinical treatment as strong evidence of liposomal-CBD’s potential to improve the lives of animal patients and potentially human patients.”

“Laminitis is a crippling condition well familiar and common in horses,” said Prof Chezy Barenholz, the Chief Scientific Officer of Innocan. “The disease results in severe pain condition, representing another big market for liposomal-CBD with great potential to treat horses. Innocan is dedicated to advancing the development of CBD-based therapeutics for various indications in both humans and animals.”

For further information and a supporting video, please see: https://youtu.be/Hgqh2WOlwJQ?si=oGgSYrGi3rkW-RC

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:

Iris Bincovich, CEO

+1 5162104025

+972-54-3012842

+442037699377

[email protected]

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-reports-breakthrough-in-a-pre-clinical-trial-liposomal-cbd-injection-restores-mobility-to-an-amputee-female-donkey-302141590.html

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania